Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Autolus Therapeutics (Nasdaq: AUTL) will participate in the Jefferies Global Healthcare Conference in London. CEO Dr. Christian Itin will appear in a fireside chat on Tuesday, November 18, 2025 at 7:30 AM EST / 12:30 PM GMT. A live webcast will be available on the company’s Events page and a replay will be archived on the website for 90 days after the presentation.
The presentation covers company updates and investor engagement; webcast access is via the company investor relations site.
Autolus Therapeutics (Nasdaq: AUTL) parteciperà alla Jefferies Global Healthcare Conference a Londra. Il CEO Dr. Christian Itin interverrà in una chiacchierata informale martedì 18 novembre 2025 alle 7:30 AM EST / 12:30 PM GMT. Un webcast in diretta sarà disponibile sulla pagina Events dell’azienda e una replica sarà archiviata sul sito per 90 giorni dopo la presentazione.
La presentazione copre aggiornamenti sull’azienda e impegno con gli investitori; l’accesso al webcast è tramite il sito IR dell’azienda.
Autolus Therapeutics (Nasdaq: AUTL) participará en la Jefferies Global Healthcare Conference en Londres. El director ejecutivo Dr. Christian Itin participará en una charla junto a la chimenea el martes 18 de noviembre de 2025 a las 7:30 a. m. EST / 12:30 p. m. GMT. Se transmitirá en vivo mediante un webcast disponible en la página de Eventos de la empresa y una repetición quedará archivada en el sitio web durante 90 días después de la presentación.
La presentación cubre actualizaciones de la empresa y el compromiso con los inversores; el acceso al webcast es a través del sitio de relaciones con inversores de la empresa.
Autolus Therapeutics (Nasdaq: AUTL)은 런던에서 열리는 Jefferies Global Healthcare Conference에 참가합니다. CEO Dr. Christian Itin은 2025년 11월 18일 화요일 오전 7:30 EST / 오후 12:30 GMT에 화롯불 대담에 출연합니다. 라이브 웹캐스트는 회사의 Events 페이지에서 이용 가능하며 발표 후 웹사이트에 90일간 재방송이 보관됩니다.
발표는 회사 업데이트와 투자자 참여를 다루며, 웹캐스트 접속은 회사 IR 사이트를 통해 가능합니다.
Autolus Therapeutics (Nasdaq: AUTL) participera à la Jefferies Global Healthcare Conference à Londres. Le PDG Dr. Christian Itin participera à une discussion au coin du feu mardi 18 novembre 2025 à 7:30 AM EST / 12:30 PM GMT. Un webcast en direct sera disponible sur la page Événements de l’entreprise et une rediffusion sera archivée sur le site pendant 90 jours après la présentation.
La présentation couvre les mises à jour de l’entreprise et l’engagement des investisseurs; l’accès au webcast se fait via le site des relations investisseurs de l’entreprise.
Autolus Therapeutics (Nasdaq: AUTL) wird an der Jefferies Global Healthcare Conference in London teilnehmen. CEO Dr. Christian Itin wird an einem Fireside-Chat am Dienstag, dem 18. November 2025 um 7:30 Uhr EST / 12:30 Uhr GMT teilnehmen. Ein Live-Webcast steht auf der Events-Seite des Unternehmens zur Verfügung, und eine Wiederholung wird 90 Tage nach der Präsentation auf der Website archiviert.
Die Präsentation behandelt Unternehmensaktualisierungen und Investoreneinbindung; der Zugriff auf den Webcast erfolgt über die Investor Relations-Seite des Unternehmens.
Autolus Therapeutics (Nasdaq: AUTL) ستشارك في مؤتمر Jefferies Global Healthcare في لندن. الرئيس التنفيذي الدكتور كريستيان إيتين سيظهر في دردشة بجلسة fireside يوم الثلاثاء 18 نوفمبر 2025 الساعة 7:30 صباحاً بتوقيت شرق الولايات المتحدة / 12:30 ظهراً بتوقيت GMT. سيكون البث المباشر متاحاً على صفحة الأحداث الخاصة بالشركة وسيتم أرشفة إعادة البث على الموقع الإلكتروني لمدة 90 يوماً بعد العرض.
يتناول العرض تحديثات الشركة وتواصلها مع المستثمرين؛ يتم الوصول إلى البث عبر موقع علاقات المستثمرين بالشركة.
- None.
- None.
LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the Jefferies Global Healthcare Conference in London.
Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Tuesday, November 18, 2025 at 7:30am EST / 12:30pm GMT.
A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
FAQ
When will Autolus (AUTL) present at the Jefferies Global Healthcare Conference?
How can I watch the Autolus (AUTL) fireside chat webcast on November 18, 2025?
Will Autolus (AUTL) provide a replay of the Jefferies conference presentation?
What topics will Autolus (AUTL) likely cover in the Jefferies fireside chat?
Where is the Jefferies Global Healthcare Conference event for Autolus (AUTL) taking place?
Who is representing Autolus (AUTL) at the Jefferies conference?
